Senti Biosciences Holdings
SNTI
26 hedge funds and large institutions have $16.6M invested in Senti Biosciences Holdings in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
13% more funds holding
Funds holding: 23 → 26 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.25% less ownership
Funds ownership: 3.08% → 2.83% (-0.25%)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
40% less capital invested
Capital invested by funds: $27.8M → $16.6M (-$11.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.26M |
| 2 |
TM
Triatomic Management
Palo Alto,
California
|
+$232K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$171K |
| 4 |
State Street
Boston,
Massachusetts
|
+$95.4K |
| 5 |
BlackRock
New York
|
+$91.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.44M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.13M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$395K |
| 4 |
KC
Kingfisher Capital
Charlotte,
North Carolina
|
-$248K |
| 5 |
Morgan Stanley
New York
|
-$240K |
SNTI Hedge Fund Activity: Q4 2022 in Review
26 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q4 2022, worth a combined $16.6M — down 40% from $27.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SNTI positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $1.26M. The largest seller was Artal Group, cutting an estimated $2.44M.
- 26 institutional investors held Senti Biosciences Holdings (SNTI) as of Q4 2022, up from 23 in Q3 2022.
- Funds reported $16.6M of Senti Biosciences Holdings stock for Q4 2022, down 40% quarter-over-quarter.
- 5 funds opened new Senti Biosciences Holdings positions in Q4 2022 and 2 closed out, a net change of +3 holders.
- The largest Senti Biosciences Holdings buyer in Q4 2022 was Vanguard Group, an estimated $1.26M added.
- The largest Senti Biosciences Holdings seller in Q4 2022 was Artal Group, an estimated $2.44M sold.
Based on aggregated 13F filings for Q4 2022.